Telitacicept: all 53 studies that test it

Page 1 of 1. Open to participants first (27), then studies with results posted, then the rest; newest registration first within each.

• IBI3034 Study in Healthy Adults and Patients With Primary IgA NephropathyNot yet recruitingNCT07886476Phase 1
• Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid ArthritisRecruitingNCT07796516Phase 2
• Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung DiseaseNot yet recruitingNCT07495033Phase 3
• Phase 3 Study of Telitacicept in Active Primary Sjögren's DiseaseRecruitingNCT07404865Phase 3
• TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM)Not yet recruitingNCT07355257Phase 2/3
• The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil TreatmentRecruitingNCT07340463Phase 2
• A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia GravisNot yet recruitingNCT07298928Not applicable
• A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)RecruitingNCT07249632Phase 3
• Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis NephritisNot yet recruitingNCT07052981Phase 3
• Telitacicept for the Treatment of Refractory RANot yet recruitingNCT07008196Phase 4
• Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia GravisNot yet recruitingNCT06827587Not applicable
• Telitacicept and Low-dose Steroids in Refractory Myasthenia GravisNot yet recruitingNCT06723548Phase 4
• Efficacy and Safety of Telitacicept in IgANRecruitingNCT06654596Not applicable
• The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous NephropathyNot yet recruitingNCT06614985Phase 2
• The Safety and Efficacy of Telitacicept in the Treatment of Systemic SclerosisRecruitingNCT06546540Phase 4
• Efficacy and Safety of Telitacicept for Prevention of Flares in SLE PatientsRecruitingNCT06394063Not applicable
• Efficacy and Safety of Telitacicept in the Treatment of Systemic SclerosisRecruitingNCT06375005Phase 2
• Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic SyndromeRecruitingNCT06125405Phase 3
• Telitacicept for the Treatment of Connective Tissue Disease-associated ThrombocytopeniaRecruitingNCT05998759Phase 2
• Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)RecruitingNCT05965284Phase 4
• Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)RecruitingNCT05962840Phase 4
• Exploring the Therapeutic Effect of Telitacicept on Lupus Erythematosus Complicated With ThrombocytopeniaNot yet recruitingNCT05929248Phase 2
• Efficacy and Safety of Telitacicept in Early SLERecruitingNCT05899907Phase 4
• A Study of Telitacicept in Lupus NephritisRecruitingNCT05680480Phase 2
• Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE PatientsRecruitingNCT05666336Phase 4
• Study of Telitacicept in Patients With Refractory IgA NephropathyNot yet recruitingNCT05596708Phase 2/3
• Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus ErythematosusRecruitingNCT05339217Phase 3
• Telitacicept for Refractory Chronic Inflammatory Demyelinating PolyneuropathyActive, not recruitingNCT07597733Not applicable
• Telitacicept for PGNMID: A Single-Arm StudyActive, not recruitingNCT07111338Phase 2
• To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA NephropathyActive, not recruitingNCT07098897Phase 3
• Immune Cell Subsets in SLE Patients Treated with TelitaciceptActive, not recruitingNCT06677801Phase 4
• The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN)Active, not recruitingNCT06656962Phase 1/2
• A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)Active, not recruitingNCT06456580Phase 3
• A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)WithdrawnNCT06456567Phase 3
• Effect of Telitacicept on Antibody Titers in Primary APS PatientsCompletedNCT06315530Phase 2
• A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Phase 3
• Study of Telitacicept in Generalized Myasthenia GravisCompletedNCT05737160Phase 3
• A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus ErythematosusCompletedNCT05687526Phase 1
• A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's SyndromeCompletedNCT05673993Phase 3
• A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)TerminatedNCT05306574Phase 3
• Telitacicept Study in Chinese Subjects With Systemic Lupus ErythematosusCompletedNCT05247203Phase 1
• Telitacicept in Primary APS PatientsTerminatedNCT05078710Phase 2
• A Study of Telitacicept for Injection (RC18) in Subjects With IgA NephropathyTerminatedNCT04905212Phase 2
• RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II TrialTerminatedNCT04625153Phase 2
• A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia GravisCompletedNCT04302103Phase 2
• A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) NephropathyCompletedNCT04291781Phase 2
• A Phase I Study of TACI-antibody Fusion Protein Injection (RC18) in Healthy Adult Chinese SubjectsCompletedNCT04235933Phase 1
• Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)CompletedNCT04082416Phase 3
• A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's SyndromeCompletedNCT04078386Phase 2
• A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum DisordersTerminatedNCT03330418Phase 3
• A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.CompletedNCT03016013Phase 3
• Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)CompletedNCT02885610Phase 2
• A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid ArthritisTerminatedNCT02882087Phase 2

← Telitacicept overview